These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30616638)

  • 1. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.
    Zhao X; Huang K; Zheng M; Duan J
    BMC Endocr Disord; 2019 Jan; 19(1):4. PubMed ID: 30616638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
    Rivera FB; Lumbang GNO; Gaid DRM; Cruz LLA; Magalong JV; Bantayan NRB; Lara-Breitinger KM; Gulati M; Bakris G
    Diabetes Obes Metab; 2024 Jun; 26(6):2209-2228. PubMed ID: 38505997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
    Kumarathurai P; Anholm C; Fabricius-Bjerre A; Nielsen OW; Kristiansen O; Madsbad S; Haugaard SB; Sajadieh A
    J Hypertens; 2017 May; 35(5):1070-1078. PubMed ID: 28129251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
    Liakos A; Lambadiari V; Bargiota A; Kitsios K; Avramidis I; Kotsa K; Gerou S; Boura P; Tentolouris N; Dimitriadis G; Tsapas A
    Diabetes Obes Metab; 2019 Mar; 21(3):517-524. PubMed ID: 30242948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Diabetes Res Clin Pract; 2017 Feb; 124():1-10. PubMed ID: 28086201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.
    Fonseca VA; Devries JH; Henry RR; Donsmark M; Thomsen HF; Plutzky J
    J Diabetes Complications; 2014; 28(3):399-405. PubMed ID: 24561125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
    von Scholten BJ; Lajer M; Goetze JP; Persson F; Rossing P
    Diabet Med; 2015 Mar; 32(3):343-52. PubMed ID: 25251901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis.
    Patoulias D; Papadopoulos C; Siskos F; Stavropoulos K; Doumas M
    Blood Press Monit; 2021 Aug; 26(4):284-287. PubMed ID: 33741774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
    Thomopoulos C; Bazoukis G; Ilias I; Tsioufis C; Makris T
    J Hypertens; 2019 Oct; 37(10):1939-1949. PubMed ID: 31157748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS; Alfayez OM; Alsheikh R
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
    Zhang Z; Zhang Q; Tan Y; Chen Y; Zhou X; Liu S; Yu J
    Front Endocrinol (Lausanne); 2023; 14():1149328. PubMed ID: 37484944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
    Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E
    Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.